Several novel therapies have recently emerged for the treatment of hematologic malignancies; several agents have demonstrated activity against T-cell lymphomas in vitro or in early clinical trials. This article discusses how these therapies may be implemented in the treatment of patients who have advanced or refractory cutaneous T-cell lymphoma.
|Original language||English (US)|
|Number of pages||8|
|Journal||Hematology/Oncology Clinics of North America|
|State||Published - Dec 2003|
ASJC Scopus subject areas